Table 2.
Association between ER, PR, HER2, Luminal subtypes, TNBC, distant metastasis and PTEN expression
| Estrogen Receptor Expression | ||||||
|---|---|---|---|---|---|---|
|
| ||||||
| PTEN | Negative | % | Positive | % | Chi- Square |
p- value |
| Loss | 36 | 41.38% | 28 | 23.93% | 8.095 | 0.044 |
| Low expression | 28 | 32.18% | 41 | 35.04% | ||
| Medium expression | 18 | 20.69% | 36 | 30.77% | ||
| High Expression | 5 | 5.75% | 12 | 10.26% | ||
| Progesterone Receptor Expression | ||||||
|
| ||||||
| PTEN | Negative | % | Positive | % | ||
|
| ||||||
| Loss | 44 | 41.12% | 20 | 20.62% | 10.576 | 0.014 |
| Low expression | 33 | 30.84% | 36 | 37.11% | ||
| Medium expression | 22 | 20.56% | 32 | 32.99% | ||
| High Expression | 8 | 7.48% | 9 | 9.28% | ||
| HER2 Expression | ||||||
|
| ||||||
| PTEN | Negative | % | Positive | % | ||
|
| ||||||
| Loss | 56 | 32.00% | 8 | 27.59% | 3.808 | 0.283 |
| Low expression | 57 | 32.57% | 12 | 41.38% | ||
| Medium expression | 45 | 25.71% | 9 | 31.03% | ||
| High Expression | 17 | 9.71% | 0 | 0.00% | ||
| Breast Cancer Luminal Subtype | ||||||
|
| ||||||
| PTEN | Non-Luminal | % | Luminal | % | ||
|
| ||||||
| Loss | 36 | 41.86% | 28 | 23.73% | 8.329 | 0.04 |
| Low expression | 27 | 31.40% | 42 | 35.59% | ||
| Medium expression | 18 | 20.93% | 36 | 30.51% | ||
| High Expression | 5 | 5.81% | 12 | 10.17% | ||
| TNBC Subtype | ||||||
|
| ||||||
| PTEN | Non-TNBC | % | TNBC | % | ||
|
| ||||||
| Loss | 34 | 25.19% | 30 | 44.12% | 8.559 | 0.036 |
| Low expression | 47 | 34.81% | 21 | 30.88% | ||
| Medium expression | 42 | 31.11% | 12 | 17.65% | ||
| High Expression | 12 | 8.89% | 5 | 7.35% | ||
| Metastasis | ||||||
|
| ||||||
| PTEN | No Mets | % | Mets | % | ||
|
| ||||||
| Negative | 105 | 62.13% | 24 | 77.42% | 2.674 | 0.102 |
| Positive | 64 | 37.87% | 7 | 22.58% | ||